According to Zhitong Finance App News, Tengsheng Pharmaceutical-B (02137) issued an announcement. On October 8, 2026, the company granted a total of 7.258,000 share options to 63 share option transferees in accordance with the terms of the 2023 share option plan, subject to acceptance by the share option transferees. At the date of this announcement, the total number of issued shares was 722 million shares (excluding treasury shares). After the total exercise of such share options granted in accordance with the grant of share options, the shares allotted and issued on this basis will account for approximately 1.0% of the total number of issued shares (excluding treasury shares) and about 1.0% of the total number of extended issued shares (excluding treasury shares and the ownership of any restricted share units granted by restricted share units to the transferees of restricted share units based on the grant of restricted share units).
On October 8, 2026, the Company granted a total of 1,389,500 restricted share units to 6 restricted share unit transferees in accordance with the terms of the 2023 share award plan, subject to acceptance by the restricted share unit transferees. At the date of this announcement, the total number of issued shares was 722 million shares (excluding treasury shares). The shares corresponding to the 1,389,500 restricted share units granted by the restricted share unit to the transferee of the restricted share unit were 1,389,500 shares, accounting for approximately 0.2% of the total number of shares issued on the date of this announcement (excluding treasury shares) and approximately 0.2% of the total number of expanded issued shares (excluding treasury shares and the exercise of any share option rights granted to share option transferees based on the grant of share options).